EA201790373A1 - Способы получения модуляторов toll-подобных рецепторов - Google Patents

Способы получения модуляторов toll-подобных рецепторов

Info

Publication number
EA201790373A1
EA201790373A1 EA201790373A EA201790373A EA201790373A1 EA 201790373 A1 EA201790373 A1 EA 201790373A1 EA 201790373 A EA201790373 A EA 201790373A EA 201790373 A EA201790373 A EA 201790373A EA 201790373 A1 EA201790373 A1 EA 201790373A1
Authority
EA
Eurasian Patent Office
Prior art keywords
toll
modulators
obtaining
methods
similar receptors
Prior art date
Application number
EA201790373A
Other languages
English (en)
Russian (ru)
Inventor
Дарин Аллен
Брендон Хит Браун
Джессика Джейд Чао
Рэндэл Л. Халькомб
Пол Хрватин
Райан Макфадден
Пол Роэтл
Эрвина Рудио
Хун Ян
Ричард Хун Чиу Юй
Original Assignee
Джилид Сайэнс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Джилид Сайэнс, Инк. filed Critical Джилид Сайэнс, Инк.
Publication of EA201790373A1 publication Critical patent/EA201790373A1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D475/00Heterocyclic compounds containing pteridine ring systems
    • C07D475/06Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/34One oxygen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52Two oxygen atoms
    • C07D239/54Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60Three or more oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
EA201790373A 2014-09-16 2015-09-14 Способы получения модуляторов toll-подобных рецепторов EA201790373A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462051044P 2014-09-16 2014-09-16
PCT/US2015/050039 WO2016044183A1 (en) 2014-09-16 2015-09-14 Methods of preparing toll-like receptor modulators

Publications (1)

Publication Number Publication Date
EA201790373A1 true EA201790373A1 (ru) 2017-08-31

Family

ID=54291584

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201790373A EA201790373A1 (ru) 2014-09-16 2015-09-14 Способы получения модуляторов toll-подобных рецепторов

Country Status (20)

Country Link
US (1) US9573952B2 (enExample)
EP (3) EP3461828B1 (enExample)
JP (4) JP6373490B2 (enExample)
KR (3) KR101978809B1 (enExample)
CN (2) CN115043840A (enExample)
AR (1) AR101882A1 (enExample)
AU (2) AU2015318062B2 (enExample)
BR (1) BR112017005100A2 (enExample)
CA (1) CA2960384C (enExample)
EA (1) EA201790373A1 (enExample)
ES (3) ES2706527T3 (enExample)
IL (1) IL250849A0 (enExample)
MX (1) MX2017003288A (enExample)
NZ (1) NZ729526A (enExample)
PL (2) PL3461828T3 (enExample)
PT (2) PT3194402T (enExample)
SG (1) SG11201701472VA (enExample)
SI (1) SI3461828T1 (enExample)
TW (2) TWI692468B (enExample)
WO (1) WO2016044183A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ593110A (en) 2008-12-09 2013-06-28 Gilead Sciences Inc pteridinone derivatives as MODULATORS OF TOLL-LIKE RECEPTORS
EA201790024A1 (ru) 2014-07-11 2017-07-31 Джилид Сайэнс, Инк. Модуляторы toll-подобных рецепторов для лечения вич
US9738646B2 (en) 2014-09-16 2017-08-22 Gilead Sciences, Inc. Solid forms of a toll-like receptor modulator
WO2019057158A1 (zh) * 2017-09-22 2019-03-28 江苏恒瑞医药股份有限公司 稠合杂芳基衍生物、其制备方法及其在医药上的应用
CN119744121A (zh) * 2022-04-26 2025-04-01 比格洛海洋科学实验室 用于生产卤代化合物的方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
JP2886570B2 (ja) 1989-09-29 1999-04-26 エーザイ株式会社 縮合ヘテロ環を有する化合物
JPH05320143A (ja) * 1992-03-18 1993-12-03 Mochida Pharmaceut Co Ltd 新規ピリミジン誘導体
TW274550B (enExample) 1992-09-26 1996-04-21 Hoechst Ag
EP0743855A1 (en) 1994-01-03 1996-11-27 Acea Pharmaceuticals, Inc. 8-aza, 6-aza and 6,8-diaza-1,4-dihydroquinoxaline-2,3-diones and the use thereof as antagonists for the glycine/nmda receptor
ZA973884B (en) 1996-05-23 1998-11-06 Du Pont Merck Pharma Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders
WO1998005661A1 (en) 1996-08-06 1998-02-12 Pfizer Inc. Substituted pyrido- or pyrimido-containing 6,6- or 6,7-bicyclic derivatives
US5693641A (en) 1996-08-16 1997-12-02 Berlex Laboratories Inc. Bicyclic pyrimidine derivatives and their use as anti-coagulants
AU4719699A (en) 1998-06-26 2000-01-17 Du Pont Pharmaceuticals Company Substituted quinoxalin-2(1h)-ones useful as hiv reverse transcriptase inhibitors
MXPA02001108A (es) 1999-09-15 2002-08-20 Warner Lambert Co Pieridinonas como inhibidores de la cinasa.
US6452325B1 (en) 2000-07-24 2002-09-17 Thermoplastic Processes, Inc. Shatterproofing of fluorescent lamps
WO2002076954A1 (en) 2001-03-23 2002-10-03 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
US6806272B2 (en) 2001-09-04 2004-10-19 Boehringer Ingelheim Pharma Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
HRP20040213A2 (en) 2001-09-04 2005-02-28 Boehringer Ingelheim Pharma Gmbh & Co.Kg Novel dihydropteridinones, method for producing the same and the use thereof as medicaments
KR100983462B1 (ko) 2003-02-26 2010-09-27 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 디하이드로프테리디논, 이의 제조방법 및 약제로서의 이의 용도
DE602005025342D1 (de) 2004-05-28 2011-01-27 Glaxosmithkline Biolog Sa Impfstoffzusammensetzungen mit virosomen und einem saponin-adjuvans
DE102004029784A1 (de) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
KR20080006004A (ko) 2005-05-04 2008-01-15 화이자 리미티드 암 및 c형 간염과 같은 바이러스 감염의 치료를 위한톨-유사 수용체 조절제인 2-아미도-6-아미노-8-옥소퓨린유도체
EP1915155A1 (en) 2005-08-03 2008-04-30 Boehringer Ingelheim International GmbH Dihydropteridinones in the treatment of respiratory diseases
EP1939201A4 (en) 2005-09-22 2010-06-16 Dainippon Sumitomo Pharma Co NEW ADENINE CONNECTION
JP5251127B2 (ja) * 2005-10-28 2013-07-31 小野薬品工業株式会社 塩基性基を含有する化合物およびその用途
WO2007103554A1 (en) * 2006-03-08 2007-09-13 Amgen Inc. Quinoline and isoquinoline derivatives as phosphodiesterase 10 inhibitors
JP2009533326A (ja) 2006-03-13 2009-09-17 メルク エンド カムパニー インコーポレーテッド 高眼圧症の治療用眼科用組成物
WO2007148064A1 (en) 2006-06-23 2007-12-27 Astrazeneca Ab Pteridine derivatives and their use as cathespin inhibitors
EP2457913B1 (en) 2006-10-19 2017-04-19 Signal Pharmaceuticals, LLC Heteroaryl compounds, compositions thereof, and methods of treatment therewith
TW200843779A (en) 2007-02-19 2008-11-16 Smithkline Beecham Corp Compounds
JP5087640B2 (ja) 2007-03-22 2012-12-05 武田薬品工業株式会社 Plk1阻害剤として有用な置換ピリミドジアゼピン
JP2010523599A (ja) * 2007-04-05 2010-07-15 シーメンス メディカル ソリューションズ ユーエスエー インコーポレイテッド クリックケミストリーを使用した炭酸脱水酵素−ixのための分子イメージングプローブの開発
US20100179109A1 (en) * 2007-04-05 2010-07-15 Baldwin Jonh J Renin inhibitors
JP5313883B2 (ja) * 2007-04-18 2013-10-09 キッセイ薬品工業株式会社 含窒素縮合環誘導体、それを含有する医薬組成物及びその医薬用途
CA2695753A1 (en) 2007-08-15 2009-02-19 Vertex Pharmaceuticals Incorporated Compounds useful as protein kinases inhibitors
WO2009022185A2 (en) 2007-08-16 2009-02-19 Astrazeneca Ab 6, 6-fused heterocycles, their pharmaceutical compositions and methos of use
WO2009067547A1 (en) 2007-11-19 2009-05-28 Takeda Pharmaceutical Company Limited Polo-like kinase inhibitors
CN101284810A (zh) * 2008-06-02 2008-10-15 秦引林 氰基吡咯烷和氰基噻唑烷衍生物
NZ593110A (en) 2008-12-09 2013-06-28 Gilead Sciences Inc pteridinone derivatives as MODULATORS OF TOLL-LIKE RECEPTORS
CA2772253C (en) * 2009-09-14 2018-02-27 Gilead Sciences, Inc. Modulators of toll-like receptors
CA2822037A1 (en) * 2010-12-20 2012-06-28 Gilead Sciences, Inc. Methods for treating hcv

Also Published As

Publication number Publication date
AU2018236824A1 (en) 2018-10-18
EP3461828A2 (en) 2019-04-03
CN107074860B (zh) 2022-07-15
BR112017005100A2 (pt) 2017-12-05
ES2845205T3 (es) 2021-07-26
AU2015318062A1 (en) 2017-03-16
ES2975520T3 (es) 2024-07-08
JP7063865B2 (ja) 2022-05-09
JP6373490B2 (ja) 2018-08-15
US20160075707A1 (en) 2016-03-17
TWI692468B (zh) 2020-05-01
KR20190053292A (ko) 2019-05-17
TW201625524A (zh) 2016-07-16
AU2018236824B2 (en) 2020-04-23
CA2960384A1 (en) 2016-03-24
PL3461828T3 (pl) 2021-07-19
EP3194402A1 (en) 2017-07-26
EP3461828B1 (en) 2020-11-25
AR101882A1 (es) 2017-01-18
JP2019214626A (ja) 2019-12-19
PT3461828T (pt) 2021-01-26
MX2017003288A (es) 2017-06-28
PT3194402T (pt) 2019-02-11
TWI780423B (zh) 2022-10-11
AU2015318062B2 (en) 2018-07-05
JP2018158953A (ja) 2018-10-11
KR102306860B1 (ko) 2021-09-30
WO2016044183A1 (en) 2016-03-24
SG11201701472VA (en) 2017-04-27
SI3461828T1 (sl) 2021-01-29
KR101978809B1 (ko) 2019-05-15
KR20210118985A (ko) 2021-10-01
PL3848375T3 (pl) 2024-05-06
EP3848375B1 (en) 2023-12-27
CN115043840A (zh) 2022-09-13
NZ729526A (en) 2018-05-25
JP2017526729A (ja) 2017-09-14
KR102457426B1 (ko) 2022-10-24
EP3194402B1 (en) 2018-11-21
EP3848375C0 (en) 2023-12-27
KR20170048592A (ko) 2017-05-08
JP7333843B2 (ja) 2023-08-25
TW202043195A (zh) 2020-12-01
EP3848375A1 (en) 2021-07-14
ES2706527T3 (es) 2019-03-29
CN107074860A (zh) 2017-08-18
JP2022051834A (ja) 2022-04-01
EP3461828A3 (en) 2019-05-01
CA2960384C (en) 2019-07-23
JP6596127B2 (ja) 2019-10-23
US9573952B2 (en) 2017-02-21
IL250849A0 (en) 2017-04-30

Similar Documents

Publication Publication Date Title
EA201790369A1 (ru) Твердые формы модулятора толл-подобного рецептора
CY1125032T1 (el) Υποκινητης mnd χιμαιρικους υποδοχεις αντιγονου
EA201790984A1 (ru) Анти-cd79b антитела и способы их применения
EA201790545A1 (ru) Антитела и иммуноконъюгаты против her2
MY192927A (en) Fused bicyclic compounds for the treatment of disease
EA201790569A1 (ru) Антитела и иммуноконъюгаты против cll-1
EA201691991A1 (ru) Мультиспецифические антитела
LT3183268T (lt) Anti-cd123 chimerinis antigeno receptorius (car), skirtas naudoti vėžio gydymui
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
LT3594238T (lt) Antikūno kompozicijos, skirtos navikų gydymui
LT3572416T (lt) Diarilo makrociklai, kaip baltymų kinazių moduliatoriai
HRP20181499T1 (hr) Bičiklički aza spojevi kao agonisti muskarinskih m1 receptora
EA201790967A1 (ru) Химерные антигенные рецепторы против cldn и способы их применения
MX369623B (es) Compuestos biciclicos fusionados para el tratamiento de enfermedades.
MX2017005920A (es) Anticuerpos anti-tim3 y metodos de uso.
MX376026B (es) Inmunoreceptores especificos de claudina-6 y epitopos de celulas t.
EA201791117A1 (ru) Частичные агонисты инсулинового рецептора
EA201691610A1 (ru) Анти-jagged1 антитела и способы применения
CL2016002731A1 (es) Herbicidas de piridazinona
EA201790395A1 (ru) Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы
MA46963A (fr) Méthodes pour déterminer le dosage de céllules car-t
EA201791421A1 (ru) Антитела против csf1r для лечения pvns
DK3265459T3 (da) Amidforbindelser som 5-ht4-receptoragonister
EA201790373A1 (ru) Способы получения модуляторов toll-подобных рецепторов
MX370897B (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades,